TIDMONC
RNS Number : 6946F
Oncimmune Holdings PLC
12 July 2023
12 July 2023
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Appointment of new leadership team
Changes to the Board
Oncimmune Holdings plc (AIM: ONC.L), the leading autoantibody
profiling company to the pharmaceutical and biotechnology industry,
is pleased to announce changes to its leadership team and its Board
of Directors.
As previously announced on 23 June 2023, following the
divestment of Oncimmune Limited, which now allows the Company to
focus on its ImmunoINSIGHTS business, Dr Adam M Hill stepped down
as the Company's Chief Executive Officer and as a director of the
Company. Oncimmune is now pleased to announce that Martin
Gouldstone will be joining Oncimmune as its new Chief Executive
Officer on 1 August 2023. Martin has over 25 years of experience in
the life science sector, including senior commercial roles at a
major CRO and most recently as Global Senior Vice President at
Owkin Inc., an AI biotech company. Martin's commercial experience
and connections will be a valuable asset in driving the Company's
future business development activities. Martin will also join the
Company's Board of Directors and regulatory disclosures in relation
to his appointment as required under Schedule 2(g) of the AIM Rules
for Companies can be found at the foot of this announcement.
In addition, after more than five years as Oncimmune's Chief
Financial Officer, Matthew Hall has decided to leave his role at
Oncimmune. Oncimmune has recruited Martin Hudson to a new role of
Finance Director, who will head the Company's finance function and
support the new Chief Executive Officer. Martin is a CIMA qualified
finance professional with over 19 years' post-qualified
international experience in large multinational and smaller
entrepreneurial environments. Martin has spent most of his career
to date in engineering and service companies, including more than
seven years with the McLaren Group and over four years at Williams
Advanced Engineering. Martin will be joining Oncimmune on 4
September 2023 and will be transitioning from Matthew over the
coming months.
Finally, after more than nine years with Oncimmune, Andrew Unitt
will be stepping down as an Independent Non-Executive Director of
the Company and as Chair of the Audit Committee on
30 September 2023. Andrew joined Oncimmune as non-executive
director in 2014 and has chaired the Audit Committee since
Oncimmune's IPO in 2016. The Company has begun a search for a new
Independent Non-Executive Director and Chair of the Audit
Committee.
Alistair Macdonald, Oncimmune ' s Chairman, said:
"On behalf of myself and the whole Board I would like to thank
Andrew and Matthew for their service to the Company over many
years. I am very pleased to welcome Martin Gouldstone and Martin
Hudson to the leadership team. Martin Gouldstone brings
considerable experience in commercialising products and services in
the life science industry and will be leading our business
development efforts. With these changes to the leadership team, we
believe that Oncimmune is now poised to begin FY2024 with the right
leadership and resources to deliver on its plan for growth, which
is based on our strong intellectual property portfolio, our master
services agreements with major pharma companies and our recently
announced long term relationship with Freenome, Inc.
"Since our last announcement in June we have continued to engage
with our shareholders to understand their views on the Company's
leadership and direction. We will continue to engage all of our
stakeholders as we move forward, and we are excited to see the
impact of a more focussed and commercially orientated leadership
team on the business."
Matthew Hall, Oncimmune's outgoing Chief Financial Officer,
said:
"I would like to thank the Board for their support over the past
five years, as we transitioned the Company from a single asset
diagnostic company to a leading autoantibody profiling pharma
services business. I wish the new management team every success as
they now capitalise on Oncimmune's industry leading position."
Martin Gouldstone, Oncimmune's incoming Chief Executive Officer,
said:
"I am delighted to be joining Oncimmune at such a pivotal time
for its business. I look forward to bringing my skills, experience
and contacts in the sector to drive the business development
efforts and deliver for stakeholders."
For further information:
Oncimmune Holdings plc
Ron Kirschner, Chief Executive Officer
contact@oncimmune.co.uk
Singer Capital Markets (Nominated Adviser and Broker)
Phil Davies, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan Bate
+44 (0)20 3829 5000
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a specialist pharmaceutical services company,
primarily focused on the growing fields of immuno-oncology,
autoimmune disease and infectious diseases. Oncimmune has a
contract discovery and development service business whose
ImmunoINSIGHTS platform delivers actionable insights into therapies
to the Company ' s pharmaceutical and biotech partners.
Our understanding of the immune system enables us to harness its
sophisticated response to disease to detect cancer earlier and to
support the development of better therapies. The key to improving
cancer survival is early detection and better selection for
therapy. As a company, we are driven by our passion to improve
cancer survival and to give people extra time.
Oncimmune ' s ImmunoINSIGHTS platform enables life science
organisations to optimise drug development and delivery, leading to
more effectively targeted and safer treatments for patients.
Oncimmune ' s ImmunoINSIGHTS service business at its discovery
research centre in Dortmund, Germany. The ImmunoINSIGHTS business
development team are based in the US and Europe.
For more information, visit www.oncimmune.com
Regulatory Disclosures
The following information regarding the appointment of Martin
Gouldstone, aged 56, is disclosed under Schedule 2(g) of the AIM
Rules for Companies:
Current Directorships Previous Directorships (within
the last five years)
* None
* hVIVO plc
* Novara Therapeutics Limited
* Orthopaedic Research UK
* Sempiternum Ltd
As at the date of this announcement, Martin Gouldstone does not
hold any ordinary shares in the Company.
Save as set out above there are no further disclosures pursuant
to Rule 17 or Schedule 2(g) of the AIM Rules for Companies in
respect of the appointment of Martin Gouldstone.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEALXFFSDDEFA
(END) Dow Jones Newswires
July 12, 2023 02:00 ET (06:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2023 to Apr 2024
